|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ADM2 |
Gene summary for ADM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ADM2 | Gene ID | 79924 |
| Gene name | adrenomedullin 2 | |
| Gene Alias | AM2 | |
| Cytomap | 22q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | Q7Z4H4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79924 | ADM2 | HCC1_Meng | Human | Liver | HCC | 2.13e-27 | 1.25e-01 | 0.0246 |
| 79924 | ADM2 | HCC2_Meng | Human | Liver | HCC | 4.33e-03 | 6.16e-02 | 0.0107 |
| 79924 | ADM2 | HCC1 | Human | Liver | HCC | 2.43e-18 | 1.95e+00 | 0.5336 |
| 79924 | ADM2 | HCC2 | Human | Liver | HCC | 2.74e-32 | 2.98e+00 | 0.5341 |
| 79924 | ADM2 | HCC5 | Human | Liver | HCC | 4.92e-36 | 1.99e+00 | 0.4932 |
| 79924 | ADM2 | S014 | Human | Liver | HCC | 3.37e-07 | 3.41e-01 | 0.2254 |
| 79924 | ADM2 | S015 | Human | Liver | HCC | 4.41e-06 | 4.12e-01 | 0.2375 |
| 79924 | ADM2 | S016 | Human | Liver | HCC | 3.78e-06 | 3.27e-01 | 0.2243 |
| 79924 | ADM2 | S027 | Human | Liver | HCC | 2.07e-06 | 5.30e-01 | 0.2446 |
| 79924 | ADM2 | S028 | Human | Liver | HCC | 4.12e-12 | 4.94e-01 | 0.2503 |
| 79924 | ADM2 | S029 | Human | Liver | HCC | 7.47e-17 | 6.92e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ADM2 | SNV | Missense_Mutation | novel | c.19N>A | p.Ala7Thr | p.A7T | Q7Z4H4 | protein_coding | deleterious(0.01) | benign(0.003) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ADM2 | SNV | Missense_Mutation | c.406N>A | p.Ser136Thr | p.S136T | Q7Z4H4 | protein_coding | tolerated(0.16) | possibly_damaging(0.755) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ADM2 | SNV | Missense_Mutation | novel | c.115N>T | p.Pro39Ser | p.P39S | Q7Z4H4 | protein_coding | tolerated(0.27) | benign(0.02) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| ADM2 | insertion | Frame_Shift_Ins | novel | c.155_156insC | p.Ala54ArgfsTer123 | p.A54Rfs*123 | Q7Z4H4 | protein_coding | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | ||
| ADM2 | SNV | Missense_Mutation | novel | c.403N>T | p.Asp135Tyr | p.D135Y | Q7Z4H4 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADM2 | SNV | Missense_Mutation | rs546959903 | c.394G>A | p.Gly132Ser | p.G132S | Q7Z4H4 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ADM2 | SNV | Missense_Mutation | rs549309630 | c.287N>T | p.Ser96Leu | p.S96L | Q7Z4H4 | protein_coding | tolerated(0.71) | benign(0) | TCGA-CV-7430-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |